

SignalSilence® p53 siRNA I

10 µM in 300 µl
(100 transfections)



Orders ■ 877-616-CELL (2355)
orders@cellsignal.com
Support ■ 877-678-TECH (8324)
info@cellsignal.com
Web ■ www.cellsignal.com

rev. 02/21/19


For Research Use Only. Not For Use In Diagnostic Procedures.

Species Cross-Reactivity: H, M, R

Description: SignalSilence® p53 siRNA I from Cell Signaling Technology (CST) allows the researcher to specifically inhibit p53 expression using RNA interference, a method whereby gene expression can be selectively silenced through the delivery of double stranded RNA molecules into the cell. All SignalSilence® siRNA products from CST are rigorously tested in-house and have been shown to reduce target protein expression by western analysis.

Background: The p53 tumor suppressor protein plays a major role in cellular response to DNA damage and other genomic aberrations. Activation of p53 can lead to either cell cycle arrest and DNA repair or apoptosis (1). p53 is phosphorylated at multiple sites *in vivo* and by several different protein kinases *in vitro* (2,3). DNA damage induces phosphorylation of p53 at Ser15 and Ser20 and leads to a reduced interaction between p53 and its negative regulator, the oncoprotein MDM2 (4). MDM2 inhibits p53 accumulation by targeting it for ubiquitination and proteasomal degradation (6,7). p53 can be phosphorylated by ATM, ATR and DNA-PK at Ser15 and Ser37. Phosphorylation impairs the ability of MDM2 to bind p53, promoting both the accumulation and activation of p53 in response to DNA damage (4,5). Chk2 and Chk1 can phosphorylate p53 at Ser20, enhancing its tetramerization, stability and activity (8,9). p53 is phosphorylated at Ser392 *in vivo* (11,12) and by CAK *in vitro* (12). Phosphorylation of p53 at Ser392 is increased in human tumors (14) and has been reported to influence the growth suppressor function, DNA binding and transcriptional activation of p53 (10,11,13). p53 is phosphorylated at Ser6 and Ser9 by CK1δ and CK1ε both *in vitro* and *in vivo* (10,15). Phosphorylation of p53 at Ser46 regulates the ability of p53 to induce apoptosis (16). Acetylation of p53 is mediated by p300 and CBP acetyltransferases. Inhibition of deacetylation suppressing MDM2 from recruiting HDAC1 complex by p19 (ARF) stabilizes p53. Acetylation appears to play a positive role in the accumulation of p53 protein in stress response (17). Following DNA damage, human p53 becomes acetylated at Lys382 (Lys379 in mouse) *in vivo* to enhance p53-DNA binding (18). Deacetylation of p53 occurs through interaction with the SIRT1 protein, a deacetylase that may be involved in cellular aging and the DNA damage response (19).

Small interfering RNA (siRNA) has been used to specifically silence p53 expression in human tumor cells (20).



Western blot analysis of extracts from HeLa cells, transfected with non-targeted (-) or SignalSilence® p53 siRNA I (+), using p53 Antibody #9282 and p42 MAP Kinase (Erk2) Antibody #9108. The p53 antibody confirms silencing of p53 expression, while the p42 MAPK antibody was used to control for loading and specificity of p53 siRNA.

Directions for Use: CST recommends transfection with 100 nM p53 siRNA I 48 to 72 hours prior to cell lysis. For transfection procedure, follow protocol provided by the transfection reagent manufacturer. Please feel free to contact CST with any questions on use.

Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.

Entrez-Gene ID #P04637
Swiss-Prot Acc. #7157

Storage: p53 siRNA I is supplied in RNase-free water. Aliquot and store at -20°C.

Please visit www.cellsignal.com for a complete listing of recommended companion products.

Background References:

- (1) Levine, A.J. (1997) *Cell* 88, 323-331.
- (2) Meek, D.W. (1994) *Semin. Cancer Biol.* 5, 203-210.
- (3) Milczarek, G.J. et al. (1997) *Life Sci.* 60, 1-11.
- (4) Shieh, S.Y. et al. (1997) *Cell* 91, 325-334.
- (5) Tibbetts, R.S. et al. (1999) *Genes Dev.* 13, 152-157.
- (6) Chehab, N.H. et al. (1999) *Proc. Natl. Acad. Sci. USA* 96, 13777-13782.
- (7) Honda, R. et al. (1997) *FEBS Lett.* 420, 25-27.
- (8) Shieh, S.Y. et al. (1999) *EMBO J.* 18, 1815-1823.
- (9) Hirao, A. et al. (2000) *Science* 287, 1824-1827.
- (10) Kohn, K.W. (1999) *Mol. Biol. Cell* 10, 2703-2734.
- (11) Hao, M. et al. (1996) *J. Biol. Chem.* 271, 29380-29385.
- (12) Lu, H. et al. (1997) *Mol. Cell. Biol.* 17, 5923-5934.
- (13) Lohrum, M. and Scheidtmann, K.H. (1996) *Oncogene* 13, 2527-2539.
- (14) Ullrich, S.J. et al. (1993) *Proc. Natl. Acad. Sci. USA* 90, 5954-5958.
- (15) Knippschild, U. et al. (1997) *Oncogene* 15, 1727-1736.
- (16) Oda, K. et al. (2000) *Cell* 102, 849-862.
- (17) Ito, A. et al. (2001) *EMBO J.* 20, 1331-1340.
- (18) Sakaguchi, K. et al. (1998) *Genes Dev.* 12, 2831-2841.
- (19) Solomon, J.M. et al. (2006) *Mol. Cell. Biol.* 26, 28-38.
- (20) Irwin, M. S. et al. (2003) *Cancer Cell* 3(4), 403-410.